164
A. De Marco et al. / European Journal of Pharmaceutical Sciences 22 (2004) 153–164
Examination of Deltabond C8 as stationary phase for measuring
lipophilicity parameters. Quant. Struct.-Act. Relat. 12, 261–268.
Altomare, C., Cellamare, S., Carotti, A., Ferappi, M., 1994. Linear sol-
vation energy relationships in reversed-phase liquid chromatography.
Examination of RP-8 stationary phases for measuring lipophilicity
parameters. Farmaco 49, 394–401.
Antithrombotic Trialists’ Collaboration, 2002. Collaborative meta-analysis
of randomized trials of antiplatelet therapy for prevention of death,
myocardial infarction, and stroke in high risk patients. Br. Med. J.
324, 71–86.
Berger, P.B., 1999. The thienopyridines in coronary artery disease. Curr.
Cardiol. Rep. 1, 192–198.
Bonina, F.P., Arenare, L., Palagiano, F., Saija, A., Nava, F., Trombetta,
D., De Caprariis, P., 1999. Synthesis, stability and pharmacological
evaluation of nipecotic acid prodrugs. J. Pharm. Sci. 88, 561–567.
Booth, R., Dias Selassie, C., Hansch, C., Santi, D.V., 1987. Quantitative
structure–activity relationship of triazine-antifolate inhibition of leish-
mania dihydrofolate reductase and cell growth. J. Med. Chem. 30,
1218–1224.
Gurbel, P.A., Bliden, K.P., Hiatt, B.L., O’Connor, C.M., 2003. Clopido-
grel for coronary stenting: response variability, drug resistance, and
the effect of pretreatment platelet reactivity. Circulation 107, 2908–
2913.
Guo, Z., Zheng, X., Thompson, W., Dugdale, M., Gollamudi, R., 2000.
New carbamoylpiperidines as human platelet aggregation inhibitors.
Bioorg. Med. Chem. 8, 1041–1058.
Ha-Duong, N.T., Dijols, S., Macherey, A.-C., Goldstein, J.A., Dansette,
P.M., Mansuy, D., 2001. Ticlopidine as a selective mechanism-based
inhibitor of human cytochrome P450 2C19. Biochemistry 40, 12112–
12122.
Hankey, G.J., 2001. Current oral antiplatelet agents to prevent atherothrom-
bosis. Cerebrovasc. Dis. 11 (Suppl. 2), 11–17.
Higuchi, M., Ikeda, I., Hirao, T., 1997. A novel synthetic metal catalytic
system. J. Org. Chem. 62, 1072–1078.
Hollopeter, G., Jantzen, H.M., Vincent, D., Li, G., England, L., Ramakr-
ishnan, V., Yang, R.B., Nurden, P., Nurden, A., Julius, D., Conley,
P.B., 2001. Identification of the platelet ADP receptor targeted by
antithrombotic drugs. Nature 409, 202–207.
Born, G.V.R., 1962. Aggregation of blood platelets by adenosine diphos-
phate (ADP) and its reversal. Nature 194, 927–929.
Brass, L., 1995. Molecular basis for platelet activation. in: Hoffman, R.,
Benz, E.J., Shattil, S.J., Furie, B., Cohen, H.J., Silberstein, L.E. (Eds.),
Hematology: Basic Principles and Practice, Churchill Livingstone,
New York, pp. 1536–1552.
Burke, J., Kraft, W.K., Greenberg, H.E., Gleave, M., Pitari, G.M., VanBu-
ren, S., Wagner, J.A., Waldman, S.A., 2003. Relationship of arachi-
donic acid concentration to cyclooxygenase-dependent human platelet
aggregation. J. Clin. Pharmacol. 43, 983–989.
Kubinyi, L., 1993. QSAR: Hansch analysis and related approaches.
in: Mannhold, R., Krogsgaard-Larsen, P., Timmerman, H. (Eds.),
Methods and Principles in Medicinal Chemistry, VCH, Weinheim,
pp. 68–77.
Kunapuli, S.P., 1998. Multiple P2 receptor subtypes on platelets: a new
interpretation of their function. Trends Pharmacol. Sci. 19, 391–
394.
Lawrence, W.P., Howell, R.D., Gollamudi, R., 1994. Antiplatelet activity
of nipecotamides in experimental thrombosis in mice. J. Pharm. Sci.
83, 222–225.
Carrupt, P.-A., Gaillard, P., Billois, F., Webber, P., Meyer, C., Perez, S.,
1995. The molecular lipophilicity potential (MLP): a new tool for
log P calculations and docking and in comparative molecular field
analysis (CoMFA). in: Pliska, V., Testa, B., Van der Waterbeemd, H.
(Eds.), Lipophilicity in Drug Action and Toxicology. VCH Publishers,
Weinheim, pp. 195–217.
De Candia, E., De Cristofaro, R., Landolfi, R., 1999. Thrombin-induced
platelet activation is inhibited by high and low-molecular weight
heparin. Circulation 99, 3308–3314.
Majerus, W., Tollesfsen, D.M., 2001. Anticoagulant, thrombolytic, and
antiplatelet drugs. in: Goodman, L.S., Gilman, A.G., Limbird, L.E.
(Eds.), The Goodman Gilman’s Pharmacological Basis of Therapeu-
tics. McGraw-Hill, New York, pp. 1519–1537.
McKee, S.A., Sane, D.C., Deliargyris, E.N., 2002. Aspirin resistance
in cardiovascular disease: a review of prevalence, mechanisms, and
clinical significance. Thromb. Haemost. 88, 711–715.
Mills, D.C., 1996. ADP receptors on platelets. Thromb. Haemost. 76,
835–856.
de Candia, M., Summo, L., Carrieri, A., Altomare, C., Nardecchia, A.,
Cellamare, S., Carotti, A., 2003. Investigation of platelet aggregation
inhibitory activity by phenyl amides and esters of piperidinecarboxylic
acids. Bioorg. Med. Chem. 11, 1439–1450.
De Cristofaro, R., De Candia, E., Picozzi, M., Landolfi, R., 1995. Con-
formational transitions linked to active site in human thrombin: effect
on the interaction with fibrinogen and the cleavable platelet receptor.
J. Mol. Biol. 245, 447–458.
Mishkel, G.J., Aguirre, F.V., Ligon, R.W., Rocha-Singh, K.J., Lucore, C.L.,
1999. Clopidogrel as adjunctive antiplatelet therapy during coronary
stenting. J. Am. Coll. Cardiol. 34, 1884–1890.
Moussa, I., Oetgen, M., Roubin, G., Colombo, A., Wang, X., Iyer, S.,
Maida, R., Collins, M., Kreps, E., Moses, J.W., 1999. Effectiveness
of clopidogrel and aspirin versus ticlopidine and aspirin in preventing
stent thrombosis after coronary stent implantation. Circulation 99,
2364–2366.
Dillingham, E.O., Lasslo, A., Carter-Burks, G., Bond, S.E., Gollamudi,
R., 1989. Relationships between chemical structure and inhibition of
ADP-stimulated human thrombocyte release of serotonin and platelet
factor 4. Biochim. Biophys. Acta 990, 128–132.
Dogné, J.-M., de Leval, X., Benoit, P., Delarge, J., Masereel, B., David,
J.-L., 2001. Recent advances in antiplatelet agents. Curr. Med. Chem.
9, 577–589.
Feng, Z., Gollamudi, R., Dillingham, E.O., Bond, S.E., Lyman, B.A., Pur-
cell, W.P., Hill, R.J., Korfmacher, W.A., 1992. Molecular determinants
of the platelet aggregation inhibitory activity of carbamoylpiperidines.
J. Med. Chem. 35, 2952–2958.
Fuster, V., Badimon, L., Badimon, J.J., Chesebro, J.H., 1992. The patho-
genesis of coronary artery disease and the acute coronary syndromes.
N. Engl. J. Med. 326, 242–250.
Patrono, C., Coller, B., Dalen, J.E., FitzGerald, G.A., Fuster, V., Gent,
M., Hirsh, J., Roth, G., 2001. Platelet-active drugs: the relationships
among dose, effectiveness, and side effects. Chest 119, 39S–63S.
Storey, F., 2001. The P2Y12 receptor as a therapeutic target in cardiovas-
cular disease. Platelets 12, 197–209.
Tanaka, A., Nakamura, K., Nakanishi, I., Fujiwara, H., 1994.
A
novel and useful descriptor for hydrophobicity, partition coefficient
micellar-water, and its application to a QSAR study of antiplatelet
agents. J. Med. Chem. 37, 4563–4566.
Tanaka, A., Fujiwara, H., 1996. Quantitative structure–activity re-
lationship study of fibrinogen inhibitors, [[4-(4-amidinophenoxy)
butanoyl]aspartyl]valine (FK633) derivatives, using a novel hydropho-
bic descriptor. J. Med. Chem. 39, 5017–5020.
Van De Graaff, E., Steinhubl, S.R., 2000. Antiplatelet medications and
their indications in preventing and treating coronary thrombosis. Ann.
Med. 32, 561–571.
Gachet, C., 2001. ADP receptors of platelets and their inhibition. Thromb.
Haemost. 86, 222–232.
Gaillard, P., Carrupt, P.-A., Testa, B., Boudon, A., 1994. Molecular
lipophilicity potential, a tool in 3D QSAR: method and applications.
J. Comput. Aided Mol. Des. 8, 83–96.
Weksler, B.B., 2000. Antiplatelet agents in stroke prevention. Combination
therapy: present and future. Cerebrovasc. Dis. 10 (Suppl. 5), 41–
48.